<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38260531</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jan</Month><Day>04</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>A Murine Model of Post-acute Neurological Sequelae Following SARS-CoV-2 Variant Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.01.03.574064</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.01.03.574064</ELocationID><Abstract><AbstractText>Viral variant is one known risk factor associated with post-acute sequelae of COVID-19 (PASC), yet the pathogenesis is largely unknown. Here, we studied SARS-CoV-2 Delta variant-induced PASC in K18-hACE2 mice. The virus replicated productively, induced robust inflammatory responses in lung and brain tissues, and caused weight loss and mortality during the acute infection. Longitudinal behavior studies in surviving mice up to 4 months post-acute infection revealed persistent abnormalities in neuropsychiatric state and motor behaviors, while reflex and sensory functions recovered over time. Surviving mice showed no detectable viral RNA in the brain and minimal neuroinflammation post-acute infection. Transcriptome analysis revealed persistent activation of immune pathways, including humoral responses, complement, and phagocytosis, and reduced levels of genes associated with ataxia telangiectasia, impaired cognitive function and memory recall, and neuronal dysfunction and degeneration. Furthermore, surviving mice maintained potent T helper 1 prone cellular immune responses and high neutralizing antibodies against Delta and Omicron variants in the periphery for months post-acute infection. Overall, infection in K18-hACE2 mice recapitulates the persistent clinical symptoms reported in long COVID patients and may be useful for future assessment of the efficacy of vaccines and therapeutics against SARS-CoV-2 variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ankita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Awadalkareem</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Aditi</LastName></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Bi-Hung</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Vikram V</ForeName><Initials>VV</Initials></Author><Author ValidYN="Y"><LastName>Kan</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Pei-Yong</ForeName><Initials>PY</Initials></Author><Author ValidYN="Y"><LastName>Samir</LastName><ForeName>Parimal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cisneros</LastName><ForeName>Irma</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tian</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Front Immunol. 2024 May 03;15:1384516. doi: 10.3389/fimmu.2024.1384516</RefSource><PMID Version="1">38765009</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>10</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38260531</ArticleId><ArticleId IdType="pmc">PMC10802283</ArticleId><ArticleId IdType="doi">10.1101/2024.01.03.574064</ArticleId><ArticleId IdType="pii">2024.01.03.574064</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>